X0306 4 2022-06-02 0 0001680581 Fulcrum Therapeutics, Inc. FULC 0001577034 Gould Robert J C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2022-06-02 4 M 0 16689 7.84 A 523319 D Common Stock 2022-06-02 4 S 0 16689 7.9191 D 506630 D Common Stock 2022-06-03 4 M 0 25551 7.84 A 532181 D Common Stock 2022-06-03 4 S 0 25551 7.9471 D 506630 D Common Stock 2022-06-06 4 M 0 24382 7.84 A 531012 D Common Stock 2022-06-06 4 S 0 24382 8.104 D 506630 D Stock Option (right to buy) 7.84 2022-06-02 4 M 0 16689 0.00 D 2029-01-21 Common Stock 16689 207891 D Stock Option (right to buy) 7.84 2022-06-03 4 M 0 25551 0.00 D 2029-01-21 Common Stock 25551 182340 D Stock Option (right to buy) 7.84 2022-06-06 4 M 0 24382 0.00 D 2029-01-21 Common Stock 24382 157958 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.59, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022. Exhibit Index: 24.1 Power of Attorney /s/ Gregory Tourangeau, as attorney-in-fact for Robert J. Gould 2022-06-06